Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 26, 2008. The report details a specific corporate action regarding the repurchase and cancellation of the company's own ordinary shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share buyback transaction:
- Shares Purchased: 2,100,000 ordinary shares of 25 pence each.
- Purchase Price: 1,090.44 pence per share.
- Treasury Shares Held: 474,194,158 shares (representing 9.12% of total voting rights).
- Shares in Issue: 5,199,982,101 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the company's share capital through the cancellation of 2,100,000 shares purchased on November 26, 2008. This action was executed under authority granted by shareholders at the Annual General Meeting on May 21, 2008. The filing does not provide comparative data against prior periods for financial performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, outlook, or discussion of risks and contingencies. It is a compliance announcement confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules and explicitly states it does not constitute an offer to purchase securities.
Key Facts for Investor Verification
- Verify the total cost of the buyback transaction (2,100,000 shares at 1,090.44 pence).
- Confirm the updated total voting rights denominator (5,199,982,101 shares) for disclosure threshold calculations.
- Note that the repurchased shares were cancelled, not held indefinitely as treasury stock, though the company continues to hold a significant treasury balance from prior purchases.
- Recognize that this filing does not contain operational or financial performance data for the period.